CeriBell (NASDAQ:CBLL) Receives $32.60 Average PT from Analysts

Shares of CeriBell (NASDAQ:CBLL) have been assigned an average rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $32.60.

A number of equities analysts have commented on CBLL shares. TD Cowen upped their price objective on shares of CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. William Blair initiated coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an “outperform” rating for the company. Canaccord Genuity Group assumed coverage on CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective on the stock. Canaccord Genuity Group increased their target price on CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, Bank of America began coverage on CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price target on the stock.

CeriBell Trading Down 0.1 %

Shares of CBLL stock opened at $26.45 on Wednesday. CeriBell has a 52-week low of $23.00 and a 52-week high of $32.75.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to analyst estimates of $17.06 million. On average, analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.